Journal
CANCER LETTERS
Volume 376, Issue 1, Pages 155-164Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.03.037
Keywords
HIF1A-AS2; Bladder cancer; LncRNAs; Tetracycline-inducible; Synthetic biology
Categories
Funding
- National Key Basic Research Program of China (973 Program) [2014CB745201]
- Chinese High-Tech (863) Program [2014AA020607]
- National Natural Science Foundation of China [81402103]
- International S&T Cooperation program of China (ISTCP) [2014DFA31050]
- National Science Foundation Projects of Guangdong Province [2014A030313717]
- Shenzhen Municipal Government of China [ZDSYS201504301722174, JCYJ20150330102720130, GJHZ20150316154912494]
- Special Support Funds of Shenzhen for Introduced High-Level Medical Team
Ask authors/readers for more resources
Various studies have indicated that long non-coding RNAs (lncRNAs) play vital roles in the cancer development and progression. LncRNA hypoxia inducible factor 1 alpha antisense RNA-2 (HIF1A-AS2) is upregulated in gastric carcinomas and knockdown of HIF1A-AS2 expression by siRNA could inhibit cell proliferation in vitro and tumorigenesis in vivo. Inspired by these observations, we hypothesized that HIF1A-AS2 possibly plays the analogous roles in bladder cancer. In our study, we first reported that HIF1A-AS2 was up-regulated in bladder cancer tissues and cells, and HIF1A-AS2 expression level in bladder cancer tissues is positively associated with advanced clinical pathologic grade and TNM phase. Cell proliferation inhibition, cell migration suppression and apoptosis induction were observed by silencing HIF1A-AS2 in bladder cancer T24 and 5637 cells. Overexpression of HIF1A-AS2 in SV-HUC-1 cells could promote cell proliferation, cell migration and anti-apoptosis. Besides, we utilized the emerging technology of medical synthetic biology to design tetracycline-inducible small hairpin RNA (shRNA) vector which specifically silenced HIFI A-AS2 in a dosage-dependent manner to inhibit the progression of human bladder cancer. In conclusion, our data suggested that HIF1A-AS2 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer. Synthetic tetracycline-on switch system that quantitatively controlled the expression of HIF1A-AS2 in bladder cancer can inhibit the progression of bladder cancer cells in a dosage-dependent manner. Our findings provide new insights into the role of the IncRNA HIF1A-AS2 in the bladder cancer. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available